Pathophysiological Explorations of Red Blood Cells (GR-Ex)

September 7, 2026 updated by: Imagine Institute
GR-Ex is a program labelled by Labex (Laboratory of Excellence) by the French Ministry of Higher Education and Research. This program aims to develop the means to improve knowledge in the physiology and pathologies of erythropoiesis, red blood cells and iron metabolism, and to develop new therapeutic protocols capable of providing added value in terms of innovation.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

3750

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Benin
      • Cotonou, Benin
        • Not yet recruiting
        • CHU Hôpital de la Mère et de l'enfant Lagune
        • Contact:
          • Jules Alao, Pr
          • Phone Number: +229 21 30 06 56
        • Principal Investigator:
          • Jules Alao, Pr
  • France
      • Amiens, France
        • Recruiting
        • CHU Amiens-Picardie
        • Principal Investigator:
          • Loic Garcon
        • Contact:
      • Antony, France
        • Recruiting
        • Hôpital Privé d'Antony
        • Contact:
          • Alexandre Morel, Dr
          • Phone Number: 01 86 86 12 34
        • Principal Investigator:
          • Alexandre Morel, Dr
      • Bobigny, France
        • Recruiting
        • Hopital Avicenne
        • Contact:
        • Principal Investigator:
          • Nathalie Ganne, Pr
      • Bordeaux, France
        • Recruiting
        • Hôpital Pellegrin
        • Contact:
        • Principal Investigator:
          • Alain Brisson, Pr
      • Clichy, France
        • Recruiting
        • Hôpital Beaujon
        • Contact:
        • Principal Investigator:
          • Camille Hego, Dr
      • Colombes, France
        • Recruiting
        • Hôpital Louis Mourier
        • Contact:
        • Principal Investigator:
          • Laurent Gouya, Pr
      • Créteil, France
        • Recruiting
        • Hôpital Henri Mondor
        • Contact:
        • Principal Investigator:
          • Jacques Pariat, Dr
      • Le Kremlin-Bicêtre, France
        • Recruiting
        • CHU Kremlin Bicetre
        • Contact:
        • Principal Investigator:
          • Corinne Guitton, Dr
      • Marseille, France
        • Recruiting
        • Hopital de la Conception
        • Contact:
        • Principal Investigator:
          • Benoit Meunier, Dr
      • Marseille, France
        • Recruiting
        • Hôpital d'Enfants de la TIMONE
        • Contact:
        • Principal Investigator:
          • Isabelle Thuret, Dr
      • Montpellier, France
        • Recruiting
        • Hopital Saint Eloi
        • Contact:
        • Principal Investigator:
          • Patricia Aguilar-Martinez, Pr
      • Niort, France
        • Recruiting
        • CHU de Niort
        • Contact:
        • Principal Investigator:
          • Sophie Deriaz, Dr
      • Paris, France
        • Recruiting
        • Hopital Saint-Antoine
        • Contact:
        • Principal Investigator:
          • Vincent Jachier, Dr
      • Paris, France
        • Recruiting
        • Hôpital Cochin
        • Principal Investigator:
          • Frédéric Pène, Pr
        • Contact:
      • Paris, France
        • Recruiting
        • Hopital Saint Louis
        • Contact:
        • Principal Investigator:
          • Flore Sicre de Fontbrune, Dr
      • Paris, France
        • Recruiting
        • Hôpital Européen Georges-Pompidou
        • Principal Investigator:
          • Jean-Benoit Arlet, Pr
        • Contact:
      • Paris, France
        • Recruiting
        • Hôpital Armand Trousseau
        • Contact:
        • Principal Investigator:
          • Marie-Hélène Odievre, Dr
      • Paris, France
        • Recruiting
        • Hopital Necker - Enfants Malades
        • Principal Investigator:
          • Olivier Hermine, Pr
        • Contact:
      • Paris, France
        • Not yet recruiting
        • Hôpital Robert Debré
        • Contact:
        • Principal Investigator:
          • Bérengère Koehl, Pr
      • Paris, France
        • Recruiting
        • Groupe Hospitalier Diaconesses Croix Saint Simon
        • Contact:
        • Principal Investigator:
          • Wladimir Mauhin, Dr
      • Paris, France
        • Recruiting
        • Institut Pasteur
        • Contact:
        • Principal Investigator:
          • Fabien Taieb, Dr
      • Rouen, France
        • Recruiting
        • CHU de Rouen
        • Contact:
        • Principal Investigator:
          • Hélène Guizouarn, Dr
      • Saint-Mandé, France
        • Recruiting
        • Hôpital national d'instruction des armées Bégin
        • Contact:
          • Sébastien Larréché, Dr
          • Phone Number: 01 43 98 52 99
        • Principal Investigator:
          • Sébastien Larréché, Dr
  • Guadeloupe
      • Pointe-à-Pitre, Guadeloupe
        • Not yet recruiting
        • CHU de la Guadeloupe
        • Contact:
        • Principal Investigator:
          • Maryse-Etienne Julan, Pr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Inclusion of patients affected by red blood cell disorder and their non affected relatives

Description

Inclusion Criteria:

  • To be affected or have a family history of disease bound to the red blood cell,
  • For adult subjects, have signed an informed consent form,
  • For minor or major under legal safeguard subjects, the form must be signed by both parents (for minors) or by the legal representative,
  • Be affiliated to health insurance.

Exclusion Criteria:

  • Being deprived of freedom

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Affected patients
Biological samples of blood for all patients. Biological samples of saliva, surgical remainder (skin, tumor, kidney,....), saliva, urine, hair.
Other: Biological sampling
Biological samples including blood, surgical remainder, urine,...
Non affected relatives
Biological samples of blood for all relatives.
Other: Biological sampling
Biological samples including blood, surgical remainder, urine,...

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Innovative markers of spleen fonctionality
Time Frame: 20 years
Retention rate (%) of red blood cells using Microsphiltration compared with non affected subjects
20 years
Quantification of inflammation in sickle cell disease
Time Frame: 20 years
Activation rate of circulating mastocytes (%)
20 years
Markers of post-artesunate hemolysis
Time Frame: 20 years
Concentration of pitted red blood cells at day 3
20 years
Correlation between transfusion yield and the storage of red blood cell bags
Time Frame: 20 years
Increasing in haemoglobin concentration at 6 hours post transfusion
20 years
Efficiency of Phosphodiesterase inhibitor on neutrophil adhesion in Sickle cell disease
Time Frame: 20 years
Proportional change in adhesion rate (%) of neutrophils measured in the peripheral blood before and after treatment with phosphodiesterase inhibitors
20 years
Quantification of mitochondria removal during erythropoiesis in SDC patients, consequences on the mature RBC
Time Frame: 20 years
Mitochondria rate and level of ROS in RBC measured by Flow Cytometry
20 years
Study of iron metabolism in Diamond-Blackfan Anemia patients
Time Frame: 20 years
Dosage of iron metabolism parameters
20 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Imagine Institute

Investigators

  • Study Director: Olivier Hermine, MD, PhD, Assistance Publique - Hôpitaux de Paris

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 16, 2017

Primary Completion (Estimated)

October 15, 2037

Study Completion (Estimated)

October 15, 2037

Study Registration Dates

First Submitted

March 23, 2018

First Submitted That Met QC Criteria

May 17, 2018

First Posted (Actual)

May 30, 2018

Study Record Updates

Last Update Posted (Actual)

September 9, 2026

Last Update Submitted That Met QC Criteria

September 7, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IMNIS2015-04

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe